MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
BPC-157 Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of a gastric juice protective protein and characterized extensively across more than 200 publications by Predrag Sikiric and colleagues at the University of Zagreb. Proposed mechanisms include upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and the nitric oxide system, modulation of dopaminergic and serotonergic pathways involved in mood and gut function, counteraction of corticosteroid-impaired healing, and acceleration of angiogenic and fibroblast-driven tissue repair in tendon, ligament, gastrointestinal mucosa, brain, and muscle injury models. Researchers study it for tendinopathy, inflammatory bowel disease, post-traumatic brain injury, ischemic stroke recovery, and post-surgical anastomotic healing in animal models. Mechanistic work is summarized in PMID 30915550 (Sikiric review 2018) and PMID 31496439 (Seiwerth 2019).
Reconstitute: Add 3 mL bacteriostatic water → 1.67 mg/mL concentration.
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL = 0.0167 mg (17 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Plasma half-life: Short in plasma (minutes by injection in rodent studies) but reportedly stable in human gastric juice for hours, providing the rationale for oral protocols in gut-targeted research applications.
Onset: Tendon and muscle healing effects in rat models are detectable on histology and functional testing within 7 to 14 days of daily dosing; unsupervised human anecdotes describe symptom relief over 2 to 4 weeks.
Regulatory status: Not approved by FDA, EMA, MHRA, or TGA for any indication. Added to the FDA 503A bulk substance category 2 list in 2023, restricting US compounding pharmacy access. WADA prohibited as of 2025 under S0.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
Interactive BPC-157 Syringe Calculator
Currently visualizing the 5 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 5mg dry powder in 3mL water yields 1.67 mg/mL. To evaluate a 250mcg dose, pull to 15.0 units (15 syringe ticks).
U-100 Syringe Representation
15.0 Units (15 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) | 12 units (0.12 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 24 units (0.24 mL) |
| Weeks 5–8+ | 600 mcg (0.6 mg) | 36 units (0.36 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 5 mg vial.
Peptide Vials (BPC-157, 5 mg each):
- check8 weeks ≈ 6 vials (25.2 mg used)
- check12 weeks ≈ 9 vials (42 mg used)
- check16 weeks ≈ 12 vials (58.8 mg used)
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- check8 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- check12 weeks (9 vials): 27 mL → 3 × 10 mL bottles
- check16 weeks (12 vials): 36 mL → 4 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100-count boxes
- check12 weeks: 168 swabs → recommend 2 × 100-count boxes
- check16 weeks: 224 swabs → recommend 3 × 100-count boxes
Mechanism of Action (MOA)
BPC-157 is a partial sequence of the larger Body Protection Compound (BPC), a fragment isolated from human gastric juice that was hypothesized by Sikiric and colleagues to underlie the remarkable healing properties of the gastrointestinal mucosa [1][2]. The synthetic 15-amino-acid peptide GEPPPGKPADDAGLV preserves the biological activity of the parent compound and is stable in gastric juice and serum, allowing oral, subcutaneous, intramuscular, and intra-articular administration with comparable downstream effects [3]. Mechanistically, BPC-157 activates several overlapping pathways. Most prominently, it upregulates VEGF receptor 2 (VEGFR2) expression on endothelial cells and increases nitric oxide synthesis through activation of the Akt-eNOS signaling axis, driving angiogenesis in injured tissue [4]. Second, it engages ERK1/2 signaling in tendon fibroblasts and muscle satellite cells, promoting cell proliferation, migration, and survival under oxidative stress [5]. Third, BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts by approximately 3-fold at the mRNA and protein levels, sensitizing those cells to endogenous growth hormone and amplifying anabolic signaling at the site of injury [6]. Fourth, BPC-157 modulates the dopaminergic and serotonergic systems, with downstream effects on stress resilience, behavioral despair models, and gut-brain axis function [3]. Finally, BPC-157 has neuromuscular junction stabilizing effects and has been shown to accelerate axonal recovery after sciatic nerve transection in rodent models. Pharmacokinetic studies are sparse; the peptide is stable in gastric juice and resistant to hydrolysis in serum compared with most peptides of similar length, but precise plasma half-life and tissue distribution data are not well characterized in humans. The peptide does not act through a single high-affinity receptor; the proposed mechanisms involve multiple parallel signaling cascades and likely indirect effects on growth factor expression. Common research routes include subcutaneous injection in the abdomen or thigh, intramuscular injection near the site of injury, oral administration in capsule form, intra-articular injection in joint research, and topical formulations in wound healing studies. Typical research dosing is 250 to 500 mcg/day subcutaneously for 4 to 8 weeks, with some protocols using 200 to 800 mcg/day orally divided in two doses for gastrointestinal research applications. Common research applications include Achilles tendinopathy and tendon rupture, rotator cuff and biceps tendon injury, anterior cruciate ligament transection and reconstruction recovery, muscle strain and laceration, gastric ulcer (where it has the strongest preclinical pedigree), inflammatory bowel disease models, post-surgical adhesion prevention, and corneal wound healing. Reported outcomes in animal models include faster return of biomechanical strength in tendon injury, reduced ulcer area in gastric and intestinal damage models, improved gut barrier integrity in inflammatory bowel disease models, increased granulation tissue formation in skin wound healing, and accelerated corneal re-epithelialization in alkali burn and abrasion models. Critical limitations include the modest size of the human evidence base (only three pilot studies in humans have been published, examining intra-articular knee pain, interstitial cystitis, and intravenous pharmacokinetics), the variability in formulation quality across research suppliers, the FDA Category 2 compounding restriction issued in late 2023 limiting US pharmacy access, and the WADA prohibition that excludes use by competitive athletes. The combination of broad preclinical evidence and very limited human data positions BPC-157 as one of the most-studied yet least-clinically-validated peptides in the regenerative space.
Clinical Trial Efficacy Highlights
- starChang and colleagues (J Appl Physiol 2011) demonstrated that BPC-157 significantly accelerated outgrowth of rat tendon explants, increased survival of tendon fibroblasts under hydrogen peroxide stress, and enhanced cell migration in scratch assays, providing the foundational mechanism of tendon healing [5].
- starChang and colleagues showed in tendon fibroblasts that BPC-157 dose- and time-dependently increased growth hormone receptor mRNA and protein expression, sensitizing these cells to growth hormone-mediated proliferation and providing a novel mechanism for amplification of anabolic signaling at injury sites [6].
- starSikiric and colleagues have published over 200 papers demonstrating that BPC-157 accelerates healing of transected Achilles tendon in rats, reduces gastric and intestinal ulcer area in models of NSAID-induced and stress-induced damage, and protects multiple organ systems in toxic and ischemic insults [3].
- starA 2024 narrative review on BPC-157 for musculoskeletal healing summarized the preclinical evidence base and noted that human data remain extremely limited, with only three pilot human studies examining BPC-157 in intra-articular knee pain, interstitial cystitis, and intravenous pharmacokinetics and safety [7].
- starIn rodent models of myotendinous junction disruption, BPC-157 administered subcutaneously after surgical transection accelerated functional recovery, restored myotendinous junction architecture on histology, and reduced inflammatory infiltrate [4][8].
- starIn animal models of corneal injury, BPC-157 administered topically as eye drops accelerated re-epithelialization, reduced inflammatory infiltrate, and supported corneal nerve recovery, suggesting potential applications in ophthalmic wound healing [9].
- starIn rodent models of NSAID-induced gastrointestinal damage, oral BPC-157 reduced ulcer area, restored mucosal integrity, and attenuated the rise in inflammatory cytokines, supporting the original gastric protective hypothesis from which the peptide was named [3].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningBPC-157 has been broadly described as well tolerated in preclinical and the limited human pilot studies, with no serious adverse events attributable to the peptide in the published literature.
- warningInjection site reactions including mild erythema, transient pain, and pruritus are the most common adverse events with subcutaneous administration, generally resolving within 24 hours.
- warningTheoretical concerns about angiogenesis-related effects on occult malignancy exist because VEGFR2-driven angiogenesis could theoretically support tumor growth; no direct clinical evidence of tumor promotion has been demonstrated, but caution is appropriate in individuals with active or recent cancer.
- warningMild gastrointestinal effects including transient nausea or bloating have been described with oral high-dose courses but are inconsistently reported across studies.
- warningLong-term safety data are essentially absent; published human exposure is limited to short-term pilot studies, and chronic dosing safety, immunogenicity, and effects on rare adverse events have not been characterized.
- warningPregnancy, lactation, and pediatric safety have not been studied; teratogenicity studies meeting modern regulatory standards have not been published.
- warningDrug-drug interactions have not been formally characterized; the peptide does not interact with cytochrome P450 enzymes, but pharmacodynamic interactions with anticoagulants and immunomodulators are theoretically possible.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical BPC-157 dosage?expand_more
Research protocols typically use 250 to 500 mcg/day subcutaneously for 4 to 8 weeks. Some protocols dose 200 to 800 mcg/day orally divided in two doses, particularly for gastrointestinal applications. Injection sites are often near the area of injury based on preclinical evidence of local effects.
How is BPC-157 used in research protocols?expand_more
Primary applications include tendon and ligament injury, muscle strain, gastric and intestinal ulcer models, inflammatory bowel disease research, and corneal wound healing. Outcome measures include functional recovery timelines, ultrasound or MRI imaging, biomechanical testing, and gastrointestinal endoscopic evaluation.
Can BPC-157 be combined with other peptides?expand_more
BPC-157 is most commonly stacked with TB-500 in research healing protocols on the rationale of complementary mechanisms (VEGFR2-driven angiogenesis plus actin-mediated cell migration). Combinations with GHK-Cu, KPV, and growth hormone secretagogues are also studied.
What are the side effects of BPC-157?expand_more
Most users report only mild injection site reactions and occasional transient gastrointestinal symptoms with oral dosing. Theoretical concerns about angiogenesis effects on occult malignancy exist but have not been confirmed clinically. Long-term safety data are sparse.
Is BPC-157 FDA approved?expand_more
No. BPC-157 is not approved by the FDA, EMA, or other major Western regulators for any indication. In late 2023 the FDA placed BPC-157 in Category 2 of its 503A compounding list, indicating that risks outweigh benefits and effectively restricting compounded pharmacy access in the United States.
Academic References & Study Citations
Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327. View Scientific Paper →
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. View Scientific Paper →
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. View Scientific Paper →
Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157. Curr Neuropharmacol. 2016;14(8):857-865. View Scientific Paper →
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. View Scientific Paper →
Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. View Scientific Paper →
Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Curr Sports Med Rep. 2025;24(8):278-289. View Scientific Paper →
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 as a therapy for the disable myotendinous junctions in rats. Biomedicines. 2021;9(11):1547. View Scientific Paper →
Lazic R, Gabric N, Dekaris I, Bosnar D, Boban-Blagaic A, Sikiric P. Gastric pentadecapeptide BPC 157 promotes corneal epithelial defect healing in rats. Coll Antropol. 2005;29(1):321-325. View Scientific Paper →
Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-2499. View Scientific Paper →